Page 116 - Read Online

McKenna et al Hypoxia in prostate cancer

YG. Hypoxia inducible factor-1 alpha-dependent epithelial to phase I study. Clin Cancer Res 2008;14:1096-104.
mesenchymal transition under hypoxic conditions in prostate cancer 36. Patterson LH. Rationale for the use of aliphatic N-Oxides of
cells. Oncol Rep 2016;36:521-7. cytotoxic anthraquinones as prodrug DNA-binding agents - a new
17. Butterworth KT, McCarthy HO, Devlin A, Ming L, Robson T, class of bioreductive agent. Cancer Metastasis Rev 1993;12:119-
McKeown SR, Worthington J. Hypoxia selects for androgen 34.
independent LNCaP cells with a more malignant geno- and 37. Raleigh SM, Wanogho E, Burke MD, McKeown SR, Patterson LH.
phenotype. Int J Cancer 2008;123:760-8. Involvement of human cytochromes P450 (CYP) in the reductive
18. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe metabolism of AQ4N, a hypoxia activated anthraquinone di-N-oxide
SW, Giaccia AJ. Hypoxia-mediated selection of cells with diminished prodrug. Int J Radiat Oncol Biol Phys 1998;42:763-7.
apoptotic potential in solid tumours. Nature 1996;379:88-91. 38. McCarthy HO, Yakkundi A, McErlane V, Hughes CM, Keilty G,
19. Ranasinghe WKB, Baldwin GS, Bolton D, Shulkes A, Ischia J, Patel Murray M, Patterson LH, Hirst DG, McKeown SR, Robson T.
O. HIF1 alpha expression under normoxia in prostate cancer-which Bioreductive GDEPT using cytochrome P450 3A4 in combination
pathways to target? J Urol 2015;193:763-70. with AQ4N. Cancer Gene Ther 2003;10:40-8.
20. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OC. The 39. McErlane V, Yakkundi A, McCarthy HO, Hughes CM, Patterson
concentration of oxygen dissolved in tissues at the time of irradiation LH, Hirst DG, Robson T, McKeown SR. A cytochrome P4502B6
as a factor in radiotherapy. Br J Radiol 1953;26:638-48. meditated gene therapy strategy to enhance the effects of radiation
21. King HW, Michael MZ, Gleadle JM. Hypoxic enhancement of or cyclophosphamide when combined with the bioreductive drug
exosome release by breast cancer cells. BMC Cancer 2012;12:421. AQ4N. J Gene Med 2005;7:851-9.
22. Turaka A, Buyyounouski MK, Hanlon AL, Horwitz EM, Greenberg 40. Yakkundi A, McErlane V, Murray M, McCarthy HO, Ward C, Hughes
RE, Movsas B. Hypoxic prostate/muscle PO2 ratio predicts for CM, Patterson LH, Hirst DG, McKeown SR, Robson T. Tumor-
outcome in patients with localized prostate cancer: long-term results. selective drug activation: a GDEPT approach utilizing cytochrome
Int J Radiat Oncol Biol Phys 2012;82:E433-9. P450 1A1 and AQ4N. Cancer Gene Ther 2006;13:598-605.
23. Zhang W, Zhou X, Yao Q, Liu Y, Zhang H, Dong Z. HIF-1-mediated 41. Nishida CR, Lee M, de Montellano PRO. Efficient hypoxic activation
production of exosomes during hypoxia is protective in renal tubular of the anticancer agent AQ4N by CYP2S1 and CYP2W1. Mol
cells. Am J Physiol Renal Physiol 2017;313:F906-F13. Pharmacol 2010;78:497-502.
24. Thery C, Zitvogel L, Amigorena S. Exosomes: composition, 42. Saggar JK, Tannock IF. Activity of the hypoxia- activated pro- drug
biogenesis and function. Nat Rev Immunol 2002;2:569-79. TH-302 in hypoxic and perivascular regions of solid tumors and
25. Ramteke A, Ting H, Agarwal C, Mateen S, Somasagara R, Hussain its potential to enhance therapeutic effects of chemotherapy. Int J
A, Graner M, Frederick B, Agarwal R, Deep G. Exosomes secreted Cancer 2014;134:2726-34.
under hypoxia enhance invasiveness and stemness of prostate 43. DiSilvestro PA, Ali S, Craighead PS, Lucci JA, Lee YC, Cohn
cancer cells by targeting adherens junction molecules. Mol Carcinog DE, Spirtos NM, Tewari KS, Muller C, Gajewski WH, Steinhoff
2015;54:554-65. MM, Monk BJ. Phase III randomized trial of weekly cisplatin and
26. Deep G, Panigrahi GK. Hypoxia-induced signaling promotes prostate irradiation versus cisplatin and tirapazamine and irradiation in Stages
cancer progression: exosomes role as messenger of hypoxic response IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis:
in tumor microenvironment. Crit Rev Oncog 2015;20:419-34. a gynecologic oncology group study. J Clin Oncol 2014;32:458-U81.
27. Fraga A, Ribeiro R, Prnicipe P, Lopes C, Medeiros R. Hypoxia 44. Steward WP, Middleton M, Benghiat A, Loadman PM, Hayward
and prostate cancer aggressiveness: a tale with many endings. Clin C, Waller S, Ford S, Halbert G, Patterson LH, Talbot D. The
Genitourin Cancer 2015;13:295-301. use of pharmacokinetic and pharmacodynamic end points to
28. Stewart GD, Ross JA, McLaren DB, Parker CC, Habib FK, Riddick determine the dose of AQ4N, a novel hypoxic cell cytotoxin,
ACP. The relevance of a hypoxic tumour microenvironment in given with fractionated radiotherapy in a phase I study. Ann Oncol
prostate cancer. BJU Int 2010;105:8-13. 2007;18:1098-103.
29. Paolicchi E, Gemignani F, Krstic-Demonacos M, Dedhar S, Mutti L, 45. Wu M, Wang X, McGregor N, Pienta KJ, Zhang J. Dynamic
Landi S. Targeting hypoxic response for cancer therapy. Oncotarget regulation of Rad51 by E2F1 and p53 in prostate cancer cells
2016;7:13464-78. upon drug-induced DNA damage under hypoxia. Mol Pharmacol
30. Wigerup C, Pahlman S, Bexell D. Therapeutic targeting of 2014;85:866-76.
hypoxia and hypoxia-inducible factors in cancer. Pharmacol Ther 46. Gu Y, Patterson AV, Atwell GJ, Chernikova SB, Brown JM,
2016;164:152-69. Thompson LH, Wilson WR. Roles of DNA repair and reductase
31. Hunter FW, Wouters BG, Wilson WR. Hypoxia-activated prodrugs: activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide
paths forward in the era of personalised medicine. Br J Cancer mustard PR-104A. Mol Cancer Ther 2009;8:1714-23.
2016;114:1071-7. 47. Evans JW, Chernikova SB, Kachnic LA, Banath JP, Sordet O,
32. Phillips RM. Targeting the hypoxic fraction of tumours using hypoxia- Delahoussaye YM, Treszezamsky A, Chon BH, Feng Z, Gu
activated prodrugs. Cancer Chemother Pharmacol 2016;77:441-57. Y, Wilson WR, Pommier Y, Olive PL, Powell SN, Brown JM.
33. Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Homologous recombination is the principal pathway for the repair of
Cancer 2011;11:393-410. DNA damage induced by tirapazamine in mammalian cells. Cancer
34. Bennewith KL, Dedhar S. Targeting hypoxic tumour cells to Res 2008;68:257-65.
overcome metastasis. BMC Cancer 2011;11:504. 48. Olcina M, Lecane PS, Hammond EM. Targeting hypoxic cells
35. Albertella MR, Loadman PM, Jones PH, Phillips RM, Rarnpling R, through the DNA damage response. Clin Cancer Res 2010;16:5624-
Burnet N, Alcock C, Anthoney A, Vjaters E, Dunk CR, Harris PA, 9.
Wong A, Lalani AS, Twelves CJ. Hypoxia-selective targeting by the 49. Lindquist KE, Cran JD, Kordic K, Kyle AH, Minchinton AI.
bioreductive prodrug AQ4N in patients with solid tumors: results of a Sensitization of hypoxic cells to ionising radiation by a hypoxia

10 Journal of Cancer Metastasis and Treatment ¦ Volume 4 ¦ March 1, 2018